Kyung Dong Pharmaceutical Valuation
Is A011040 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of A011040 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: A011040 (₩6750) wird über unserer Schätzung des Fair Value (₩5313.99) gehandelt.
Deutlich unter dem Marktwert: A011040 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A011040?
Other financial metrics that can be useful for relative valuation.
| What is A011040's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₩172.30b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | -8.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A011040's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
A214390 Kyongbo Pharmaceutical | 0.8x | n/a | ₩177.9b |
A002620 Jeil Pharma Holdings | 0.2x | n/a | ₩162.3b |
A002390 HANDOK | 0.4x | n/a | ₩187.6b |
A023910 Daihan PharmaceuticalLtd | 0.8x | 8.6% | ₩165.2b |
A011040 Kyung Dong Pharmaceutical | 1.1x | n/a | ₩172.3b |
Price-To-Sales gegen Gleichaltrige: A011040 ist auf der Grundlage des Price-To-Sales Verhältnisses (1.1x) im Vergleich zum Durchschnitt der Vergleichsgruppe (0.9x) teuer.
Price to Earnings Ratio vs Industry
How does A011040's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: A011040 ist teuer, wenn man sein Price-To-Earnings Verhältnis (26.8x) mit dem KR Pharmaceuticals Branchendurchschnitt (21.8x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is A011040's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.1x |
| Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von A011040 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.